Literature DB >> 27576304

A complication probability planning study to predict the safety of a new protocol for intracranial tumour radiotherapy in dogs.

C Rohrer Bley1, V Meier1, P Schwarz1, M Roos2, J Besserer1,3.   

Abstract

Technical advances make it possible to deliver radiation therapy for canine intracranial tumours in fewer fractions, under the assumption of equivalent tumour control. With the aim of estimating the late toxicity risk profile for various tumour sizes and locations, the present paper evaluates the normal tissue complication probability (NTCP) values for the intracranial organs at risk. By making isoeffect calculations, a new 10-fraction radiation protocol was developed with the same tumour control probability (TCP) as a currently used 20-fraction standard protocol, and complication risk profiles for brain, brainstem and optic chiasm were modelled using a representative population of 64 dogs with brain tumours. For >59% of cases, the new 10-fraction protocol yielded an acceptable, low risk estimate of late toxicity (<10%). Our calculations suggest that it may be safe to treat small to intermediate-sized tumours that are neither located near the optic chiasm nor at the brainstem with 10 daily fractions of 4.35 Gy.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  brain tumour; canine; fractionation; radiation; risk; toxicity

Mesh:

Year:  2016        PMID: 27576304     DOI: 10.1111/vco.12265

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  8 in total

1.  Definitive-intent intensity-modulated radiation therapy provides similar outcomes to those previously published for definitive-intent three-dimensional conformal radiation therapy in dogs with primary brain tumors: A multi-institutional retrospective study.

Authors:  Nathaniel Van Asselt; Neil Christensen; Valeria Meier; Carla Rohrer Bley; Sarah Laliberte; Valerie J Poirier; Noopur Desai; Yi Chen; Michelle Turek
Journal:  Vet Radiol Ultrasound       Date:  2020-05-01       Impact factor: 1.363

2.  Outcome After Radiation Therapy in Canine Intracranial Meningiomas or Gliomas.

Authors:  TomÁs Rodrigues MagalhÃes; JÉrÔme BenoÎt; SlavomÍra NÉČovÁ; Susan North; Felisbina LuÍsa Queiroga
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

3.  Using biologically based objectives to optimize boost intensity-modulated radiation therapy planning for brainstem tumors in dogs.

Authors:  Valeria Meier; Jürgen Besserer; Carla Rohrer Bley
Journal:  Vet Radiol Ultrasound       Date:  2019-10-10       Impact factor: 1.363

4.  Can volumetric modulated arc radiation therapy reduce organ at risk dose in stage 4 sinonasal tumors in dogs treated with boost irradiation?

Authors:  Valeria Meier; Felicitas Czichon; Linda Walsh; Carla Rohrer Bley
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

5.  Treatment of intracranial neoplasia in dogs using higher doses: A randomized controlled trial comparing a boosted to a conventional radiation protocol.

Authors:  Chris Staudinger; Valeria Meier; Katrin Beckmann; Maximilian Körner; Carla Rohrer Bley
Journal:  J Vet Intern Med       Date:  2022-06-30       Impact factor: 3.175

6.  Comparative evaluation of a novel, moderately hypofractionated radiation protocol in 56 dogs with symptomatic intracranial neoplasia.

Authors:  Philip Schwarz; Valeria Meier; Alena Soukup; Randi Drees; Jürgen Besserer; Katrin Beckmann; Malgorzata Roos; Carla Rohrer Bley
Journal:  J Vet Intern Med       Date:  2018-10-11       Impact factor: 3.333

7.  Definitive-intent uniform megavoltage fractioned radiotherapy protocol for presumed canine intracranial gliomas: retrospective analysis of survival and prognostic factors in 38 cases (2013-2019).

Authors:  M Debreuque; P De Fornel; I David; F Delisle; M N Ducerveau; P Devauchelle; J L Thibaud
Journal:  BMC Vet Res       Date:  2020-10-31       Impact factor: 2.741

Review 8.  Ocular and periocular radiation toxicity in dogs treated for sinonasal tumors: A critical review.

Authors:  Friederike Wolf; Valeria S Meier; Simon A Pot; Carla Rohrer Bley
Journal:  Vet Ophthalmol       Date:  2020-04-12       Impact factor: 1.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.